Key result
EVTOP strategy quantifies ~500 unique EV phosphopeptides from microliter volumes of plasma.
Why the study?
Monitoring disease-relevant phosphorylation events in circulating biofluids is highly appealing but remains technically challenging.
The EVTOP strategy enables highly sensitive phosphoproteomic profiling of extracellular vesicles from microliter volumes of biofluids, with potential applications in monitoring disease outcomes.
Supports sensitive EV phosphoproteomics from microliter biofluids; leaves open clinical translation for disease monitoring.
Many biological processes are regulated through dynamic protein phosphorylation. Monitoring disease‐relevant phosphorylation events in circulating biofluids is highly appealing but also technically challenging. We introduce here a functionally tunable material and a strategy, extracellular vesicles to phosphoproteins (EVTOP), which achieves one‐pot extracellular vesicles (EVs) isolation, extraction, and digestion of EV proteins, and enrichment of phosphopeptides, with only a trace amount of starting biofluids. EVs are efficiently isolated by magnetic beads functionalized with TiIV ions and a membrane‐penetrating peptide, octa‐arginine R8+, which also provides the hydrophilic surface to retain EV proteins during lysis. Subsequent on‐bead digestion concurrently converts EVTOP to TiIV ion‐only surface for efficient enrichment of phosphopeptides for phosphoproteomic analyses. The streamlined, ultra‐sensitive platform enabled us to quantify 500 unique EV phosphopeptides with only a few μL of plasma and over 1200 phosphopeptides with 100 μL of cerebrospinal fluid (CSF). We explored its clinical application of monitoring the outcome of chemotherapy of primary central nervous system lymphoma (PCNSL) patients with a small volume of CSF, presenting a powerful tool for broad clinical applications.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2023) studied Primary central nervous system lymphoma (PCNSL). EVTOP (extracellular vesicles to phosphoproteins) strategy was evaluated on Quantification of unique EV phosphopeptides. The EVTOP strategy enabled the quantification of 500 unique EV phosphopeptides from a few μL of plasma and over 1200 phosphopeptides from 100 μL of CSF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: